Related references
Note: Only part of the references are listed.Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
Alberto Alvarez-Larran et al.
BLOOD (2012)
Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study
Henrik Frederiksen et al.
BLOOD (2011)
Higher risk of primary cancers after polycythaemia vera and vice versa
Mahdi Fallah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Role of Genetic Susceptibility in Development of Treatment-Related Adverse Outcomes in Cancer Survivors
Smita Bhatia
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2011)
XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase
Jill O. Fuss et al.
DNA REPAIR (2011)
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population
Camilla Nielsen et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
Magnus Bjorkholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
Jean-Jacques Kiladjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients
A. Pardanani et al.
LEUKEMIA (2010)
Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Alessandro M. Vannucchi et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
Amy V. Jones et al.
NATURE GENETICS (2009)
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
Ola Landgren et al.
BLOOD (2008)
DNA repair gene XPD Polymorphisms and cancer risk: A meta-analysis based on 56 case-control studies
Fan Wang et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
Francesco Passamonti et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
F. Cervantes et al.
LEUKEMIA (2008)
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
Animesh Pardanani et al.
BLOOD (2008)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus
S. Burgstaller et al.
LEUKEMIA (2007)
Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
Naseema Gangat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Base-excision repair of oxidative DNA damage
Sheila S. David et al.
NATURE (2007)
A common genetic variant in XPD associates with risk of 5q-and 7q-deleted acute myeloid leukemia
Alexandra G. Smith et al.
BLOOD (2007)
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients
N. Gangat et al.
LEUKEMIA (2007)
SNPStats:: a web tool for the analysis of association studies
Xavier Sole et al.
BIOINFORMATICS (2006)
DNA repair polymorphisms and cancer risk in non-smokers in a cohort study
G Matullo et al.
CARCINOGENESIS (2006)
Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders
MJ Burkitt et al.
BLOOD (2006)
Long-term incidence of hematological evolution in three french prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia
Jean-Jacques Kiladjian et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
G Finazzi et al.
BLOOD (2005)
Hydroxyurea-associated squamous dysplasia
C Sanchez-Palacios et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy
JM Allan et al.
BLOOD (2004)
The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia
C Seedhouse et al.
BLOOD (2002)
ERCC2/XPD gene polymorphisms and cancer risk
S Benhamou et al.
MUTAGENESIS (2002)
How nucleotide excision repair protects against cancer
EC Friedberg
NATURE REVIEWS CANCER (2001)
The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases
AR Lehmann
GENES & DEVELOPMENT (2001)
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial
G Finazzi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Share Paper
